OncoMatch/Clinical Trials/NCT06919666
NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Is NCT06919666 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies NT219 for head and neck cancer.
Treatment: NT219 — Fixed dose NT219 weekly plus pembrolizumab every 3 weeks or cetuximab weekly to be continued until progression, unacceptable toxicity, or investigator or participant decision.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) cps >1 (cps >1)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: anti-cancer biologic agent
Exception: within 4 weeks prior to Study Day 1
Prior anti-cancer biologic agent within 4 weeks prior to Study Day 1
Cannot have received: chemotherapy
Exception: within 2 weeks prior to Study Day 1
prior chemotherapy, targeted small molecular therapy, or radiation therapy within 2 weeks prior to Study Day 1
Cannot have received: targeted small molecular therapy
Exception: within 2 weeks prior to Study Day 1
prior chemotherapy, targeted small molecular therapy, or radiation therapy within 2 weeks prior to Study Day 1
Cannot have received: radiation therapy
Exception: within 2 weeks prior to Study Day 1
prior chemotherapy, targeted small molecular therapy, or radiation therapy within 2 weeks prior to Study Day 1
Lab requirements
Blood counts
anc >1500, and platelets >100,000
Kidney function
calculated creatinine clearance >60 ml/min
Liver function
total bilirubin < 1.5x the uln, alt and ast <5x the uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Universtiy of Colorado Hospital · Aurora, Colorado
- UCHealth Highlands Ranch Hospital · Highlands Ranch, Colorado
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify